Tacrolimus Rescue Therapy in Steroid- & OKT3-Resistant Rejection after Renal Transplantation.
- Author:
Seung Kee MIN
1
;
In Mok JUNG
;
Seong Soo KIM
;
Jongwon HA
;
Jung Kee CHUNG
;
Cu Rie AHN
;
Sang Joon KIM
Author Information
1. Department of Surgery, Seoul National University, College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Tacrolimus rescue therapy;
Refractory rejection;
Renal transplantation;
PTLD
- MeSH:
Creatinine;
Follow-Up Studies;
Graft Survival;
Humans;
Immunosuppression;
Kidney Transplantation*;
Male;
Muromonab-CD3;
Nephrectomy;
Retrospective Studies;
Risk Factors;
Tacrolimus*;
Transplants
- From:The Journal of the Korean Society for Transplantation
1998;12(2):261-268
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Acute rejection in renal transplantation is a major risk factor threatening the longterm graft survival. Acute rejections refractory to conventional anti-rejection therapy using steroid pulse or antilymphocyte preparations occur in minority, preceding to progressive deterioration of renal function and graft loss. Recent reports showed that tacrolimus rescue therapy in this refractory rejections has converted rejection process. In order to evaluate the clinical outcome of tacrolimus rescue therapy in refractory rejections, we performed a retrospective study. Since April 1997, we performed tacrolimus rescue therapy intent-to-treat for steroid- or OKT3- resistant rejections in 5 patients. All rejections were histologically confirmed according to Banff criteria. As conventional antirejection therapy, steroid pulse therapy (solumedrol 500~1000 mg iv for 3 days) or OKT3 therapy (5 mg/day for 14 days) was performed. The outcome of the rescue therapy is classified into three categories by the change of serum creatinine level or the histologic findings; Improvement-return of serum creatinine level (sCr) to or below the prerejection baseline (nadir) level, Stabilization-arrested sCr increase, Failure-progressive deterioration of renal function, or graft loss. All were men and the mean age was 38 years. Living related- & unrelated-donor transplantation were 2 and 3 cases respectively. Immunosuppression were done with CsA Pd+ (3) or CsA+ Pd+ AZA (2). Acute rejection grades according to Banff criteria were mild (2) or moderate (3). The mean interval between transplantation and tacrolimus conversion was 54.4 days. The outcome was as follows; improvement 2 cases, stabilization 1 case and failure 2 cases. During 3~10 months followup PTLD occured in 1 case, treated with graft nephrectomy and no other complications in other 4 cases. In conclusion, we can convert ongoing refractory rejections to steroid and OKT3 therapy by tacrolimus rescue therapy in 60% (3/5) successfully. Although longterm followup result is necessary to confirm the efficacy and safety of the tacrolimus rescue therapy, the result of this early trial is so good that we may try tacrolimus in refractory rejections for rejection reversal.
